Greta A Bushnell1, Stephen Crystal2, Mark Olfson3. 1. Rutgers School of Public Health, Piscataway, and the Rutgers Center for Pharmacoepidemiology and Treatment Science, New Brunswick, New Jersey. Electronic address: gbushnell@ifh.rutgers.edu. 2. Institute for Health, Health Care Policy and Aging Research at Rutgers University in New Brunswick, New Jersey. 3. Columbia University Vagelos College of Physicians and Surgeons, Columbia University Mailman School of Public Health, and the New York State Psychiatric Institute in New York.
Abstract
OBJECTIVE: To estimate trends of annual antipsychotic medication use by privately insured young children (aged 2-7 years) in the United States, and to describe the clinical and treatment characteristics of these children. METHOD: The study population included young children from a nationwide commercial claims database (2007-2017). We estimated annual antipsychotic use by age and sex, defined as the number of children dispensed an antipsychotic per year divided by the number enrolled. We described clinical diagnoses and mental health service use in those with prescription antipsychotic use in 2009 and 2017. RESULTS: Annual antipsychotic use in young children was 0.27% in 2007, peaked at 0.29% in 2009, and statistically significantly declined to 0.17% by 2017 (linear trend: -0.017% per year, 95% CI: -0.018 to -0.016). Antipsychotic use was higher in boys than in girls. A greater proportion of antipsychotic users received a mental disorder diagnosis in 2017 (89%) than in 2009 (86%, p < .01). The most common clinical diagnoses in antipsychotic users, under a hierarchical classification, were pervasive developmental disorder (2009 = 27%, 2017 = 38%, p < .01), conduct or disruptive behavior disorder (2009 = 15%, 2017 = 21%, p < .01), and attention-deficit/hyperactivity disorder (2009 = 24%, 2017 = 18%, p < .01). Among 2017 antipsychotic users, 32% had 4+ psychotherapy claims, 43% had a psychiatrist visit, and the majority used another psychotropic medication, most commonly a stimulant (boys = 57%, girls = 50%). CONCLUSION: In privately insured young children, antipsychotic use declined from 2009 to 2017, with shifts toward indications with some supporting evidence. Nevertheless, a majority of use remains off label and for conditions lacking effectiveness and safety data. Improving antipsychotic prescribing in young children remains a challenge.
OBJECTIVE: To estimate trends of annual antipsychotic medication use by privately insured young children (aged 2-7 years) in the United States, and to describe the clinical and treatment characteristics of these children. METHOD: The study population included young children from a nationwide commercial claims database (2007-2017). We estimated annual antipsychotic use by age and sex, defined as the number of children dispensed an antipsychotic per year divided by the number enrolled. We described clinical diagnoses and mental health service use in those with prescription antipsychotic use in 2009 and 2017. RESULTS: Annual antipsychotic use in young children was 0.27% in 2007, peaked at 0.29% in 2009, and statistically significantly declined to 0.17% by 2017 (linear trend: -0.017% per year, 95% CI: -0.018 to -0.016). Antipsychotic use was higher in boys than in girls. A greater proportion of antipsychotic users received a mental disorder diagnosis in 2017 (89%) than in 2009 (86%, p < .01). The most common clinical diagnoses in antipsychotic users, under a hierarchical classification, were pervasive developmental disorder (2009 = 27%, 2017 = 38%, p < .01), conduct or disruptive behavior disorder (2009 = 15%, 2017 = 21%, p < .01), and attention-deficit/hyperactivity disorder (2009 = 24%, 2017 = 18%, p < .01). Among 2017 antipsychotic users, 32% had 4+ psychotherapy claims, 43% had a psychiatrist visit, and the majority used another psychotropic medication, most commonly a stimulant (boys = 57%, girls = 50%). CONCLUSION: In privately insured young children, antipsychotic use declined from 2009 to 2017, with shifts toward indications with some supporting evidence. Nevertheless, a majority of use remains off label and for conditions lacking effectiveness and safety data. Improving antipsychotic prescribing in young children remains a challenge.
Authors: Nancy Scotto Rosato; Christoph U Correll; Elizabeth Pappadopulos; Alanna Chait; Stephen Crystal; Peter S Jensen Journal: Pediatrics Date: 2012-05-28 Impact factor: 7.124
Authors: Jennifer C Seida; Janine R Schouten; Khrista Boylan; Amanda S Newton; Shima S Mousavi; Amy Beaith; Ben Vandermeer; Donna M Dryden; Normand Carrey Journal: Pediatrics Date: 2012-02-20 Impact factor: 7.124
Authors: Stephen Crystal; Mark Olfson; Cecilia Huang; Harold Pincus; Tobias Gerhard Journal: Health Aff (Millwood) Date: 2009-07-21 Impact factor: 6.301
Authors: Stephen Crystal; Thomas Mackie; Miriam C Fenton; Shahla Amin; Sheree Neese-Todd; Mark Olfson; Scott Bilder Journal: Health Aff (Millwood) Date: 2016-06-01 Impact factor: 6.301
Authors: Ferrán Catalá-López; Brian Hutton; Amparo Núñez-Beltrán; Matthew J Page; Manuel Ridao; Diego Macías Saint-Gerons; Miguel A Catalá; Rafael Tabarés-Seisdedos; David Moher Journal: PLoS One Date: 2017-07-12 Impact factor: 3.240